Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20769696 | 0.80 | NQO1 (0.52) | RAB9ACYP11B1CYP11B2CYP1A2CYP2A6 | |
| SCHEMBL22229790 | 0.80 | PLAU (0.43) | NCF1NOS3NOS1NOS2ROCK1 | |
| SCHEMBL16637714 | 0.75 | ROCK2 (0.56) | ROCK1RAB9AEGFRNPC1 | |
| SCHEMBL22229649 | 0.74 | NOS3 (0.38) | NCF1NOS3NOS1NOS2ROCK1 | |
| SCHEMBL16637499 | 0.73 | ROCK2 (0.57) | NCF1NOS3NOS1NOS2ROCK1 | |
| SCHEMBL16637613 | 0.73 | ROCK2 (0.49) | ROCK1RAB9AEGFRNPC1 | |
| SCHEMBL16637607 | 0.72 | ROCK2 (0.66) | ROCK1RAB9ACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1488532 | 0.67 | NPC1 (0.59) | NCF1NOS3NOS1NOS2RAB9A | |
| SCHEMBL1598487 | 0.67 | NCF1 (1.00) | NCF1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9848539 | 0.67 | ALDH1A1 (0.51) | NOS3NOS1NOS2RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3055301-B1 | (2-(5-ISOINDOLIN-2-YL)PYRIMIDIN-4-YL)-AMINE DERIVATIVES AS RHO KINASE INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | KADMON CORP LLC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10125144-B2 | Rho kinase inhibitors | KADMON CORPORATION, LLC (US) | 2018-11-13 | — | — | US | disclosed |
| US-20170112832-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20160237095-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2016-08-18 | — | — | US | disclosed |
| EP-3055301-A1 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015157556-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015054317-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237095-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | NCF1 3190/4885NOS3 544/4885NOS1 292/4885 |
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | NCF1 1185/4885NOS3 1600/4885NOS1 1773/4885 |
| US-10125144-B2 | Rho kinase inhibitors | ROCK2, ROCK1, RHOA | NCF1 3190/4885NOS3 544/4885NOS1 292/4885 |
| US-20170112832-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOA | NCF1 301/4885NOS3 615/4885NOS1 682/4885 |
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | NCF1 334/4885NOS3 734/4885NOS1 1026/4885 |
| US-11311541-B2 | Treatment of GVHD | ROCK2, ROCK1, RHOA | NCF1 301/4885NOS3 615/4885NOS1 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.